Description
WINSTROL 50 – Stanozolol 50mg/ml (Water-Based)
WINSTROL 50 delivers 50mg/ml of Stanozolol in a water-based injectable solution, engineered to promote lean muscle development, increased vascularity, and enhanced athletic performance. Known for its ability to reduce subcutaneous water retention, it provides a dry, hard look highly valued in cutting phases and competition prep.
Unlike many anabolic agents, Winstrol does not aromatize into estrogen, making it a preferred choice for users seeking clean gains without the risk of bloating. Its anabolic-to-androgenic ratio supports strength gains, speed, and endurance—making it a staple among performance-driven athletes.
Application:
Best applied in cutting cycles of 6–8 weeks. Particularly effective when combined with testosterone or DHT-based compounds to preserve lean mass while reducing body fat. May be administered every other day due to its short half-life.
Important Note:
Due to its hepatotoxicity, even in injectable form, liver support and regular enzyme monitoring are essential. May negatively affect cholesterol levels and joint comfort. Should not be used for extended periods.
All products sold by ORYVION are intended for laboratory research purposes only and are not approved for human consumption, medical use, or veterinary applications. These compounds are not classified as dietary supplements or pharmaceuticals.
ORYVION operates strictly within the legal frameworks of the jurisdictions in which it conducts business. Sales are limited to countries and regions where the possession and use of research chemicals are permitted by law. It is the sole responsibility of the purchaser to ensure compliance with local, national, and international laws and regulations.
By purchasing, the customer affirms that they are at least 21 years of age, legally authorized to receive such materials, and fully aware of their intended use. ORYVION disclaims all liability for misuse, improper handling, or any consequences resulting from non-compliant use of these products.
ORYVION complies with relevant provisions under EU’s Pharmaceutical and Medical Device Act, as well as applicable international guidelines regarding non-pharmaceutical research compounds.